Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center
Objective. To evaluate the effectiveness and safety of transarterial chemoembolization (TACE) combined with immune checkpoint inhibition (camrelizumab) plus an antiangiogenic agent (apatinib) for advanced hepatocellular carcinoma (HCC). Methods. Between March 2019 and April 2021, the clinical data o...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2022/7982118 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553680201580544 |
|---|---|
| author | Jin-Xing Zhang Yu-Xing Chen Chun-Gao Zhou Jin Liu Sheng Liu Hai-Bin Shi Qing-Quan Zu |
| author_facet | Jin-Xing Zhang Yu-Xing Chen Chun-Gao Zhou Jin Liu Sheng Liu Hai-Bin Shi Qing-Quan Zu |
| author_sort | Jin-Xing Zhang |
| collection | DOAJ |
| description | Objective. To evaluate the effectiveness and safety of transarterial chemoembolization (TACE) combined with immune checkpoint inhibition (camrelizumab) plus an antiangiogenic agent (apatinib) for advanced hepatocellular carcinoma (HCC). Methods. Between March 2019 and April 2021, the clinical data of 38 patients diagnosed with advanced HCC who initially received TACE combined with camrelizumab plus apatinib were reviewed retrospectively. The objective response rate (ORR) and disease control rate (DCR) according to modified response evaluation criteria in solid tumors, progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were evaluated. Results. At 2-3 months after initial therapy, the ORR and DCR was 50.0% (19/38) and 76.3% (29/38), respectively. The median PFS and OS were 7.3 months (range: 1.0–22.6 months) and 13.5 months (range: 2.3–24.3 months), respectively. Treatment-related AEs (grades 3-4) were observed in 25 patients (67.8%). No treatment-related deaths occurred. Conclusion. The combination of TACE with camrelizumab plus apatinib for the treatment of patients with advanced HCC showed promising efficacy and a manageable safety profile. |
| format | Article |
| id | doaj-art-56080aec528e4403a1fa50095acd99c5 |
| institution | Kabale University |
| issn | 2291-2797 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology and Hepatology |
| spelling | doaj-art-56080aec528e4403a1fa50095acd99c52025-02-03T05:53:30ZengWileyCanadian Journal of Gastroenterology and Hepatology2291-27972022-01-01202210.1155/2022/7982118Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single CenterJin-Xing Zhang0Yu-Xing Chen1Chun-Gao Zhou2Jin Liu3Sheng Liu4Hai-Bin Shi5Qing-Quan Zu6Department of Interventional RadiologyDepartment of Interventional RadiologyDepartment of Interventional RadiologyDepartment of Clinical Medicine Research InstitutionDepartment of Interventional RadiologyDepartment of Interventional RadiologyDepartment of Interventional RadiologyObjective. To evaluate the effectiveness and safety of transarterial chemoembolization (TACE) combined with immune checkpoint inhibition (camrelizumab) plus an antiangiogenic agent (apatinib) for advanced hepatocellular carcinoma (HCC). Methods. Between March 2019 and April 2021, the clinical data of 38 patients diagnosed with advanced HCC who initially received TACE combined with camrelizumab plus apatinib were reviewed retrospectively. The objective response rate (ORR) and disease control rate (DCR) according to modified response evaluation criteria in solid tumors, progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were evaluated. Results. At 2-3 months after initial therapy, the ORR and DCR was 50.0% (19/38) and 76.3% (29/38), respectively. The median PFS and OS were 7.3 months (range: 1.0–22.6 months) and 13.5 months (range: 2.3–24.3 months), respectively. Treatment-related AEs (grades 3-4) were observed in 25 patients (67.8%). No treatment-related deaths occurred. Conclusion. The combination of TACE with camrelizumab plus apatinib for the treatment of patients with advanced HCC showed promising efficacy and a manageable safety profile.http://dx.doi.org/10.1155/2022/7982118 |
| spellingShingle | Jin-Xing Zhang Yu-Xing Chen Chun-Gao Zhou Jin Liu Sheng Liu Hai-Bin Shi Qing-Quan Zu Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center Canadian Journal of Gastroenterology and Hepatology |
| title | Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center |
| title_full | Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center |
| title_fullStr | Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center |
| title_full_unstemmed | Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center |
| title_short | Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center |
| title_sort | efficacy and safety of the combination of transarterial chemoembolization with camrelizumab plus apatinib for advanced hepatocellular carcinoma a retrospective study of 38 patients from a single center |
| url | http://dx.doi.org/10.1155/2022/7982118 |
| work_keys_str_mv | AT jinxingzhang efficacyandsafetyofthecombinationoftransarterialchemoembolizationwithcamrelizumabplusapatinibforadvancedhepatocellularcarcinomaaretrospectivestudyof38patientsfromasinglecenter AT yuxingchen efficacyandsafetyofthecombinationoftransarterialchemoembolizationwithcamrelizumabplusapatinibforadvancedhepatocellularcarcinomaaretrospectivestudyof38patientsfromasinglecenter AT chungaozhou efficacyandsafetyofthecombinationoftransarterialchemoembolizationwithcamrelizumabplusapatinibforadvancedhepatocellularcarcinomaaretrospectivestudyof38patientsfromasinglecenter AT jinliu efficacyandsafetyofthecombinationoftransarterialchemoembolizationwithcamrelizumabplusapatinibforadvancedhepatocellularcarcinomaaretrospectivestudyof38patientsfromasinglecenter AT shengliu efficacyandsafetyofthecombinationoftransarterialchemoembolizationwithcamrelizumabplusapatinibforadvancedhepatocellularcarcinomaaretrospectivestudyof38patientsfromasinglecenter AT haibinshi efficacyandsafetyofthecombinationoftransarterialchemoembolizationwithcamrelizumabplusapatinibforadvancedhepatocellularcarcinomaaretrospectivestudyof38patientsfromasinglecenter AT qingquanzu efficacyandsafetyofthecombinationoftransarterialchemoembolizationwithcamrelizumabplusapatinibforadvancedhepatocellularcarcinomaaretrospectivestudyof38patientsfromasinglecenter |